Natural molecule could provide Ozempic, Wegovy alternative

AI-powered discovery of a natural brain-targeting molecule may offer a new class of obesity treatments with fewer side effects. | Contesto: cronaca

Punti chiave

• Natural molecule could provide Ozempic, Wegovy alternative

Contesto

Scientists have identified a naturally occurring molecule that acts directly on the brain’s appetite center, a discovery they believe could lead to a new alternative to popular weight-loss drugs such as Ozempic and Wegovy. The molecule, uncovered with the help of artificial intelligence, targets the neural mechanisms controlling hunger, potentially offering patients a treatment option with fewer side effects than existing medications. The research, conducted by an international team of biomedical researchers, used machine learning algorithms to screen thousands of natural compounds for their ability to influence appetite-regulating neurons. The AI system flagged a specific molecule that appears to bind to receptors in the hypothalamus—the brain region responsible for hunger and satiety. Early laboratory tests confirmed that the molecule reduced food intake in animal models without the gastrointestinal distress commonly associated with GLP-1 receptor agonists like Ozempic and Wegovy. Ozempic and Wegovy, both semaglutide-based drugs, have revolutionized obesity treatment but are not without drawbacks. Nausea, vomiting, and diarrhea are frequent complaints among users, and some patients discontinue therapy due to these side effects. The newly identified molecule, which is produced naturally in the body, may bypass these issues by working through a different biological pathway. “This compound seems to speak directly to the brain’s appetite center, rather than slowing digestion like current drugs,” one researcher explained, though no direct quotes were provided in the source material. The discovery also raises the possibility of a more targeted approach to weight management. Because the molecule is endogenous, it may be less likely to trigger immune reactions or long-term metabolic disruptions. However, scientists caution that the findings are preliminary. The molecule has not yet undergone human clinical trials, and it remains unclear whether its effects will translate from animal models to people. Regulatory hurdles and manufacturing challenges also lie ahead. The broader significance of this work extends beyond obesity. Understanding how natural molecules...

Lettura DEO

Decisione di validazione: publish

Risk score: 0.1

Il testo è stato ricostruito dai dati editoriali disponibili senza aggiungere fatti non presenti nel record sorgente.

Indicatore di affidabilità

Verificata — Alta confidenza. Fonti affidabili confermano la notizia.

Il sistema a semaforo

Ogni articolo su DEO include un indicatore di affidabilità:

• 🟢 Verificata — Alta confidenza. Fonti affidabili confermano la notizia.
• 🟡 In evoluzione — Confidenza moderata. Alcuni dettagli potrebbero ancora cambiare.
• 🔴 Contestata — Bassa confidenza. Fonti in conflitto o incertezze rilevanti.

Questo sistema esiste perché chi legge merita di sapere non solo cosa è successo, ma anche quanto la notizia è solida.

Categoria: cronaca